Director's Perspective | Riptide Health

Where This Begins

My mother was remarkable. Highly educated — two bachelor's degrees — she was the kind of person who didn't slow down as she aged, she accelerated. She ran her first marathon in her forties. In her fifties she was still backpacking through parts of Africa and Asia, climbing mountains, moving through the world with an energy and curiosity most people half her age couldn't match.

Then, over the course of five years, Lewy Body disease took all of it.

For those unfamiliar, Lewy Body dementia is caused by the abnormal accumulation of alpha-synuclein protein aggregates — called Lewy bodies — within brain cells.¹ These deposits disrupt normal neuronal signalling across regions governing cognition, movement, and autonomic function. It is progressive, it is relentless, and to date there is no disease-modifying treatment of any kind. Every available intervention manages symptoms only.²

I remember sitting with her near the end and seeing it in her eyes — that specific, heartbreaking recognition of her own decline. Her mind knew what was happening. She could still see herself clearly enough to know she was disappearing. That awareness, trapped behind a body and a brain that no longer responded, is not something I can unknow.

It is the reason Riptide Health exists.

The Question I Couldn't Stop Asking

In the years following her decline, I found myself drawn to a question that felt almost too simple: why does modern medicine almost always arrive after the damage is done?

This is not a criticism of medical professionals — it is an observation about the framework itself. The dominant model of intervention is reactive and symptomatic. Pain? Block the signal. Infection? Suppress the population. Cognitive decline? Slow the visible deterioration. These are valuable tools. But they are tools designed to manage consequences, not address origins.

"The dominant model of intervention is reactive and symptomatic. These are valuable tools — but they are tools designed to manage consequences, not address origins."

Injury recovery is a clear example. Non-steroidal anti-inflammatory drugs (NSAIDs) are the standard of care for musculoskeletal injuries. They are effective at reducing pain and inflammation. However, peer-reviewed research has consistently demonstrated that long-term NSAID use may actually impair the regenerative processes that produce structural tissue repair — suppressing the very inflammatory signals that initiate healing.^{3, 4} The symptom is managed. The recovery may be compromised.

The same framework applies to immune function. Over-the-counter cold and flu preparations work by blocking symptom-generating pathways — fever suppression, decongestant action, analgesic relief.⁵ They do not modulate immune competence. They do not accelerate viral clearance. They make the experience more tolerable while the immune system works independently to resolve the underlying infection. That is not a failure of the medications — it is simply their design. They were never intended to do more.

The honest question, then, is not whether these strategies work within their own design parameters. They do. The question is whether those design parameters are ambitious enough.

A Different Kind of Signal

Peptides are not pharmaceuticals in the conventional sense. They are short-chain amino acid sequences — the same molecular language the body already uses to regulate its own internal processes. Rather than blocking, suppressing, or overriding biological pathways, they operate as signalling molecules, interacting with receptors the body already possesses and amplifying processes it is already capable of performing.⁶

The distinction matters mechanistically. BPC-157, a peptide derived from a protein found naturally in gastric juice, has been shown in research settings to support angiogenesis, stimulate collagen synthesis, and promote fibroblast activity — the actual cellular machinery of tissue repair, not just the suppression of its symptomatic signals.⁷ TB-500, a synthetic analogue of Thymosin Beta-4, has demonstrated similar regenerative properties, supporting actin regulation and cellular migration in wound healing models.⁸

In the context of immune function, Thymalin — a polypeptide derived from thymic tissue — has been studied for its capacity to support T-cell differentiation and proliferation, the foundational mechanisms of adaptive immune competence.⁹ This is not symptomatic relief. This is engagement with the biological infrastructure of immune function itself — an infrastructure that progressively declines with age as thymic output diminishes.

The research in this space is early by the standards of clinical medicine. Rigorous, large-scale human trials are ongoing and necessary. But the mechanistic basis is not speculative — it is grounded in well-established biology.

The Question My Mother's Illness Made Personal

Lewy Body disease, as I came to understand it through years of research after her diagnosis, is fundamentally a failure of cellular maintenance. Alpha-synuclein misfolding and aggregation is a process that likely begins years or decades before the first clinical symptom.¹⁰ The disease is not sudden — it is the endpoint of a very long, very silent process of cellular deterioration that the body's natural repair mechanisms were unable to keep pace with.

This is where the emerging research on longevity-focused peptides becomes personally compelling to me. Epitalon, a tetrapeptide developed from research by Professor Vladimir Khavinson, has been studied for its effects on telomerase activation — the enzyme responsible for maintaining the protective caps of chromosomes that shorten with each cell division and are fundamentally linked to cellular aging.¹¹ Semax, a neuropeptide derived from ACTH, has demonstrated in research models an upregulation of Brain-Derived Neurotrophic Factor (BDNF) — a protein essential to neuronal survival, synaptic plasticity, and cognitive function — with preliminary evidence suggesting potential relevance to Alzheimer's disease models.¹²

I am not suggesting these compounds would have saved my mother. I am not qualified to make that claim, and the research does not support it. What I am saying is that the question of whether proactive cellular support — engaging the body's own maintenance mechanisms before the point of failure — could alter trajectory in neurodegenerative conditions is a question worth taking seriously. And increasingly, researchers are.

"The question is not whether intervention is possible after decline begins. The question is whether we start the conversation earlier."

Why I Am Not Waiting

I understand that aging and injury are inevitable. I have watched what inevitable looks like up close, and I have no illusions about it.

But what if there is a way of making it less painful? What if there is a way of reducing the impacts — not by fighting the body's processes, but by supporting them? The work is being done. The research is accumulating. And while I understand completely that rigorous clinical validation is required before these compounds can be administered in professional therapeutic contexts, there is already enough evidence to make me want to explore this space personally.

The evidence also tells me I am not alone in that position.

Riptide Health exists because I believe that access to research-grade compounds, transparent information, and honest scientific context is something people deserve to have — not because we are making medical claims, but because the conversation is worth having. We provide compounds for research purposes. What people do with their own curiosity and their own bodies, informed by their own reading of the science, is ultimately their decision to make.

My mother never had the option to ask these questions early enough. I intend to ask them now. And if asking them out loud means that someone else starts asking them too — then this article has done its job.

I have nothing to lose.

Cited References

1. Spillantini MG, Goedert M. Alpha-synuclein biology in Lewy body diseases. Cell Mol Life Sci. 2016;73(7):1359–1374. PMC4288216
2. Outeiro TF et al. Insights into the management of Lewy body dementia. Front Neurol. 2024. PMC10849442
3. Mackey AL, Kjaer M. The rehabilitation of muscle after injury — the role of anti-inflammatory drugs. Scand J Med Sci Sports. 2013.
4. Mehallo CJ et al. Do NSAIDs Impair Healing of Musculoskeletal Injuries? Rheum-Live. 2023.
5. Allan GM, Arroll B. Prevention and treatment of the common cold. CMAJ. 2014. PMC10324571
6. Kastin AJ (ed). Handbook of Biologically Active Peptides. Academic Press. 2013.
7. Chang CH et al. The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026.
8. Goldstein AL et al. Thymosin Beta-4: A Multi-Functional Regenerative Peptide. Expert Opin Biol Ther. 2012.
9. Khavinson VK et al. The Use of Thymalin for Immunocorrection and Molecular Correction. Biomedicines. 2021. PMC8365293
10. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2(7):492–501.
11. Khavinson VK et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003. PMID: 12937682.
12. Dolotov OV et al. Semax and its derivative improve cognitive function in Alzheimer's disease model. PMC. 2025. PMC12755871